Thus, reactivation of the MAPK/ERK pathway is intrinsic to the development of resistance to vemurafenib, and SHP2, a key protein downstream of RTK signaling, synergistically promotes resistance to vemurafenib in thyroid cancer. Here, PTPN11 is linked to thyroid gland carcinoma.